Eosinophils in Chronic Urticaria: Supporting or Leading Actors?

World Allergy Organization Journal

Alberto Tedeschi³  Massimo Cugno¹  Riccardo Asero² 

[1] Department of Internal Medicine, University of Milan and IRCCS Foundation Maggiore Hospital, Mangiagalli and Regina Elena, Milan, Italy;Allergy Unit, Clinica San Carlo, Paderno Dugnano (Milan), Italy;Allergy and Clinical Immunology Unit, IRCCS Foundation Maggiore Hospital, Mangiagalli and Regina Elena, Milan, Italy

关键词: tissue factor;    VEGF;    eosinophils;    mastcells;    chronic urticaria;   

Others  :  1180824
DOI  :  10.1097/WOX.0b013e3181bb965f

【 摘 要 】

Although their number may be increased in skin lesions, eosinophils have been rather neglected as possible participants to the pathogenesis of chronic urticaria because of the absence of peripheral eosinophilia in patients with this disease. However, recent data suggest a potentially relevant role played by activated eosinophils both in triggering the tissue factor pathway of coagulation cascade and as a source of vascular endothelial growth factor. Such phenomena seem more pronounced in patients showing a more severe disease. The present study will rediscuss the potential role of this cell line in chronic urticaria in the light of these recent observations.

【 授权许可】

   
2009 World Allergy Organization; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Grattan CEH, Francis DM, Hide M, Greaves MW: Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin Exp Allergy 1991, 21:695-704.
• [2]Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993, 328:1599-1604.
• [3]Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, et al.: Serum IgG autoantibodies directed against the alpha chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995, 96:2606-2612.
• [4]Ferrer M, Kinet JP, Kaplan AP: Comparative studies of functional and binding assays for IgG anti-FcεRIaα (α-subunit). J Allergy Clin Immunol 1998, 101:672-676.
• [5]Ferrer M, Nakazawa K, Kaplan AP: Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999, 104:169-172.
• [6]Kikuchi Y, Kaplan AP: A role for C5a in augmenting IgE-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002, 109:114-118.
• [7]Mari A: Allergy-like asthma and rhinitis. A cross-sectional survey of a respiratory cohort and a diagnostic approach using the autologous serum skin test. Int Arch Allergy Immunol 2004, 133:29-39.
• [8]Guttman-Yassky E, Bergman R, Maor C, Mamorsky M, Pollack S, Shahar E: The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals. J Eur Acad Dermatol Venereol 2007, 21:35-39.
• [9]Eckman JA, Hamilton RG, Saini SS: Independent evaluation of a commercial test for "autoimmune" urticaria in normal and chronic urticaria subjects. J Invest Dermatol 2009, 129:1584-1586.
• [10]Taskapan O, Kutlu A, Karabudak O: Evaluation of autologous serum skin test results in patients with chronic idiopathic urticaria, allergic/ non-allergic asthma or rhinitis and healthy people. Clin Exp Dermatol 2008, 33:754-758.
• [11]Spector SL, Tan RA: Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190-193.
• [12]Sands MF, Blume JW, Schwartz SA: Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007, 120:979-981.
• [13]Godse KV: Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008, 74:157-158.
• [14]Sheikh J: Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria. Ann Allergy Asthma Immunol 2008, 100:88-89.
• [15]Dreyfus DH: Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol 2008, 100:624-625.
• [16]Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A: Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999, 103:1143-1147.
• [17]Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanoletti T, Miadonna A: Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy 2001, 31:1105-1110.
• [18]Elias J, Boss E, Kaplan A: Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocyrtes, monocytes and mast cells. J Allergy Clin Immunol 1986, 78:914-918.
• [19]Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002, 109:694-700.
• [20]Sabroe R, Poon E, Orchard G, Lane D, Francis D, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-Fcepsilon or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103:484-493.
• [21]Peters M, Schroeter A, Kephard G, Gleich G: Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol 1983, 81:39-43.
• [22]Smith CH, Kepley C, Schwartz LB, Lee TH: Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995, 96:360-4.
• [23]Grattan CE, Boon A, Eady R, Winkelmann R: The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Immunol 1990, 93:198-204.
• [24]Kaplan A: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114:465-474.
• [25]Grattan CE, Winkelmann RK, Leiferman KM: Eosinophil major basic protein in autologous serum and saline skin tests in chronic idiopathic urticaria. Br J Dermatol 1997, 136:132-148.
• [26]Asero R, Tedeschi A, Lorini M, Gerosa M, Meroni P, Riboldi P: Circulating stem cell factor in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2003, 91:79-81.
• [27]Tedeschi A, Lorini M, Asero R: No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. Clin Exp Dermatol 2005, 30:171-175.
• [28]Tedeschi A, Lorini M, Suli C, Asero R: Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity. Clin Exp Dermatol 2007, 32:568-570.
• [29]Asero R, Tedeschi A, Riboldi P, Cugno M: Plasma of chronic urticaria patients shows signs of thrombin generation and its intradermal injection causes wheal-and-flare reaction much more frequently than autologous serum. J Allergy Clin Immunol 2006, 117:1113-1117.
• [30]Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, et al.: Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007, 119:705-710.
• [31]Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M: Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008, 63:176-180.
• [32]Razin E, Marx G: Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984, 133:3282-3285.
• [33]Kido H, Fukusen N, Katunuma M, Morita T, Iwanaga S: Tryptase from rat mast cells converts bovine prothrombin to thrombin. Biochem Biophys Res Commun 1985, 132:613-619.
• [34]Asero R, Madonini E: Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria. J Investig Allergol Clin Immunol 2006, 16:19-23.
• [35]Tedeschi A, Cottini M, Asero R: Simultaneous occurrence of chronic autoimmune urticaria and non-allergic asthma: a common mechanism? Eur Ann Allergy Clin Immunol 2009, 41:56-59.
• [36]Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R: Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009, 148:170-174.
• [37]Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, et al.: Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007, 109:995-1002.
• [38]Puccetti A, Bason C, Simeoni S, Millo E, Tinazzi F, et al.: In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005, 35:1599-1607.
• [39]Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G: The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004, 24:271-281.
• [40]Lampinen M, Carlson M, Håkansson LD, Venge P: Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004, 59:793-805.
• [41]Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M: Plasma levels and skin-eosinophil expression of vascular endothelial growth factor (VEGF) in patients with chronic urticaria 2009 May 27. , in press.
• [42]Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentation. Development 1992, 114:521-532.
• [43]Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
• [44]Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F: Human peripheral blood eosinophils induce angiogenesis. Int J Biochem J Biol 2005, 37:628-636.
• [45]Bhattacharyya SP, Drucker I, Reshef T, Kirshenbaum AS, Metcalfe DD, Mekori YA: Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact. J Leukoc Biol 1998, 63:337-341.
• [46]Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA: Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol 2001, 167:4008-4016.
• [47]Confino-Cohen R, Aharoni D, Goldberg A, Gurevitch I, et al.: Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 2002, 109:349-356.